Immune Checkpoint Inhibitors and Other Immune Therapies in Breast Cancer: A New Paradigm for Prolonged Adjuvant Immunotherapy
暂无分享,去创建一个
[1] C. Barrios,et al. Atezolizumab With Neoadjuvant Anti–Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2–Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial , 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Quintavalle,et al. Exosomal microRNAs synergistically trigger stromal fibroblasts in breast cancer , 2022, Molecular therapy. Nucleic acids.
[3] V. Iranzo González-Cruz,et al. Programmed Death-Ligand 1 (PD-L1) as Immunotherapy Biomarker in Breast Cancer , 2022, Cancers.
[4] A. Messori,et al. The Degree of Programmed Death-Ligand 1 (PD-L1) Positivity as a Determinant of Outcomes in Metastatic Triple-Negative Breast Cancer Treated With First-Line Immune Checkpoint Inhibitors , 2022, Cureus.
[5] Jiang Chen,et al. The developing landscape of combinatorial therapies of immune checkpoint blockade with DNA damage repair inhibitors for the treatment of breast and ovarian cancers , 2021, Journal of Hematology & Oncology.
[6] A. Graczyk-Jarzynka,et al. The Immune Landscape of Breast Cancer: Strategies for Overcoming Immunotherapy Resistance , 2021, Cancers.
[7] F. Mendes,et al. Immunotherapy in Breast Cancer: When, How, and What Challenges? , 2021, Biomedicines.
[8] N. Lee,et al. Currently Used Laboratory Methodologies for Assays Detecting PD-1, PD-L1, PD-L2 and Soluble PD-L1 in Patients with Metastatic Breast Cancer , 2021, Cancers.
[9] Xueda Hu,et al. Single-cell analyses reveal key immune cell subsets associated with response to PD-L1 blockade in triple-negative breast cancer. , 2021, Cancer cell.
[10] Fengchun Zhang,et al. Safety and Efficacy of the Rechallenge of Immune Checkpoint Inhibitors After Immune-Related Adverse Events in Patients With Cancer: A Systemic Review and Meta-Analysis , 2021, Frontiers in Immunology.
[11] Frederick M. Howard,et al. The emerging role of immune checkpoint inhibitors for the treatment of breast cancer , 2021, Expert opinion on investigational drugs.
[12] D. Tavares,et al. Immunotherapy using PD-1/PDL-1 inhibitors in metastatic triple-negative breast cancer: A systematic review , 2021, Oncology reviews.
[13] Xiaoling Hu,et al. Tumor-derived exosomes drive immunosuppressive macrophages in a pre-metastatic niche through glycolytic dominant metabolic reprogramming. , 2021, Cell metabolism.
[14] B. Czerniecki,et al. Nivolumab and Stereotactic Radiosurgery for Patients With Breast Cancer Brain Metastases: A Nonrandomized, Open-Label Phase 1b Study , 2021, Advances in radiation oncology.
[15] E. Winer,et al. Nivolumab in combination with cabozantinib for metastatic triple-negative breast cancer: a phase II and biomarker study , 2021, NPJ breast cancer.
[16] C. Diorio,et al. Breast Cancer Treatments: Updates and New Challenges , 2021, Journal of personalized medicine.
[17] A. Schneeweiss,et al. First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis. , 2021, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] J. Bergh,et al. Discordance of PD-L1 status between primary and metastatic breast cancer: A systematic review and meta-analysis. , 2021, Cancer treatment reviews.
[19] J. Zhai,et al. Efficacy and Safety of Anti-PD-1/ PD-L1 Monotherapy for Metastatic Breast Cancer: Clinical Evidence , 2021, Frontiers in Pharmacology.
[20] Anh Nguyen-Duc,et al. PD-L1 Immunohistochemistry Assay Comparison in Atezolizumab Plus nab-Paclitaxel–Treated Advanced Triple-Negative Breast Cancer , 2021, Journal of the National Cancer Institute.
[21] E. Bremer,et al. The Role of Macrophages in Cancer Development and Therapy , 2021, Cancers.
[22] N. Adel. Current treatment landscape and emerging therapies for metastatic triple-negative breast cancer. , 2021, The American journal of managed care.
[23] R. Yerushalmi,et al. Efficacy and safety of neoadjuvant immune checkpoint inhibitors in early-stage triple-negative breast cancer: a systematic review and meta-analysis , 2021, Journal of Cancer Research and Clinical Oncology.
[24] L. Conti,et al. The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy , 2021, Frontiers in Oncology.
[25] V. Sivaganesh,et al. Emerging Immunotherapies against Novel Molecular Targets in Breast Cancer , 2021, International journal of molecular sciences.
[26] R. Reis,et al. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC) , 2021, Journal of Clinical Pathology.
[27] I. Wistuba,et al. PD-L1 as a biomarker of response to immune-checkpoint inhibitors , 2021, Nature Reviews Clinical Oncology.
[28] X. Zhi,et al. Tumor cell-secreted exosomal miR-22-3p inhibits transgelin and induces vascular abnormalization to promote tumor budding. , 2021, Molecular therapy : the journal of the American Society of Gene Therapy.
[29] Anh Nguyen-Duc,et al. Atezolizumab and nab-Paclitaxel in Advanced Triple-Negative Breast Cancer: Biomarker Evaluation of the IMpassion130 Study , 2021, Journal of the National Cancer Institute.
[30] I. Bièche,et al. Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial , 2021, Nature Medicine.
[31] A. Jacinto,et al. Circulating low density neutrophils of breast cancer patients are associated with their worse prognosis due to the impairment of T cell responses , 2021, bioRxiv.
[32] R. Scolyer,et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. , 2020, Pathology.
[33] M. Piccart,et al. Immunotherapy for early breast cancer: too soon, too superficial, or just right? , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[34] Ting Zhang,et al. Tumor-Associated Macrophages in Tumor Immunity , 2020, Frontiers in Immunology.
[35] L. Teran,et al. Overview of New Treatments with Immunotherapy for Breast Cancer and a Proposal of a Combination Therapy , 2020, Molecules.
[36] A. Hartmann,et al. Understanding PD-L1 Testing in Breast Cancer: A Practical Approach , 2020, Breast Care.
[37] Sung-Bae Kim,et al. Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial. , 2020, The Lancet. Oncology.
[38] H. Iwata,et al. Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): a randomised, double-blind, phase 3 trial , 2020, The Lancet.
[39] P. Hegde,et al. A pan-cancer analysis of PD-L1 immunohistochemistry and gene amplification, tumor mutation burden and microsatellite instability in 48,782 cases , 2020, Modern Pathology.
[40] S. Gulati,et al. Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. , 2020, The Lancet. Oncology.
[41] W. Olejarz,et al. Exosomes in Angiogenesis and Anti-angiogenic Therapy in Cancers , 2020, International journal of molecular sciences.
[42] S. Kim,et al. Homologous repair deficiency score for identifying breast cancers with defective DNA damage response , 2020, Scientific Reports.
[43] P. Ellis,et al. Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.
[44] J. Crown,et al. Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer. , 2020, Seminars in cancer biology.
[45] Yan Sun,et al. PD-L1+ exosomes from bone marrow-derived cells of tumor-bearing mice inhibit antitumor immunity , 2020, Cellular & Molecular Immunology.
[46] Franziska Michor,et al. Pharmacokinetic Profiles Determine Optimal Combination Treatment Schedules in Computational Models of Drug Resistance , 2020, Cancer Research.
[47] M. Dowsett,et al. Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer , 2020, Nature Communications.
[48] E. Winer,et al. A phase Ib study of pembrolizumab (pembro) plus trastuzumab emtansine (T-DM1) for metastatic HER2+ breast cancer (MBC). , 2020 .
[49] D. Cescon,et al. KEYLYNK-009: A phase II/III, open-label, randomized study of pembrolizumab (pembro) plus olaparib vs pembro plus chemotherapy after induction with first-line pembro plus chemotherapy in patients with locally recurrent inoperable or metastatic triple-negative breast cancer (TNBC). , 2020 .
[50] Takahiro Watanabe,et al. Prognostic Significance of Neutrophil-to-lymphocyte Ratio in Luminal Breast Cancers With Low Levels of Tumour-infiltrating Lymphocytes , 2020, AntiCancer Research.
[51] L. Farahmand,et al. Breast cancer: Biology, biomarkers, and treatments. , 2020, International immunopharmacology.
[52] H. Russnes,et al. ICON: a randomized phase IIb study evaluating immunogenic chemotherapy combined with ipilimumab and nivolumab in patients with metastatic hormone receptor positive breast cancer , 2020, Journal of Translational Medicine.
[53] A. Oza,et al. Manage wisely: poly (ADP-ribose) polymerase inhibitor (PARPi) treatment and adverse events , 2020, International Journal of Gynecological Cancer.
[54] S. Tolaney,et al. Role of Immunotherapy in Triple-Negative Breast Cancer. , 2020, Journal of the National Comprehensive Cancer Network : JNCCN.
[55] P. Ferrari,et al. Minimal residual disease in advanced or metastatic solid cancers: the G0-G1 state and immunotherapy are key to unwinding cancer complexity. , 2020, Seminars in cancer biology.
[56] S. Stevanović,et al. Immunogenicity and Immune Silence in Human Cancer , 2019, SSRN Electronic Journal.
[57] K. Takabe,et al. Current status and limitations of immunotherapy for breast cancer. , 2020, Surgery.
[58] Deepak Kgk,et al. Tumor Microenvironment: Challenges and Opportunities in Targeting Metastasis of Triple Negative Breast Cancer. , 2020, Pharmacological research.
[59] Qifeng Yang,et al. Metastatic heterogeneity of breast cancer: Molecular mechanism and potential therapeutic targets. , 2020, Seminars in cancer biology.
[60] P. Ferrari,et al. A new immunotherapy schedule in addition to first-line hormone therapy for metastatic breast cancer patients in a state of clinical benefit during hormone therapy , 2020, Journal of Molecular Medicine.
[61] J. Behravan,et al. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development , 2020, Archivum Immunologiae et Therapiae Experimentalis.
[62] A. Jemal,et al. Cancer statistics, 2020 , 2020, CA: a cancer journal for clinicians.
[63] P. Hegde,et al. Top 10 Challenges in Cancer Immunotherapy. , 2020, Immunity.
[64] H. Ellis,et al. PI3K Inhibitors in Breast Cancer Therapy , 2019, Current Oncology Reports.
[65] P. Ferrari,et al. Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports , 2019, International journal of molecular sciences.
[66] E. Winer,et al. Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial. , 2019, The Lancet. Oncology.
[67] M. Redondo,et al. Immunotherapy: A Challenge of Breast Cancer Treatment , 2019, Cancers.
[68] A. Ribeiro,et al. Impact of breast cancer cells´ secretome on the brain metastatic niche remodeling. , 2019, Seminars in cancer biology.
[69] A. Lopez‐Beltran,et al. PD-L1 assessment in urothelial carcinoma: a practical approach. , 2019, Annals of translational medicine.
[70] I. Duarte,et al. Metabolic crosstalk in the breast cancer microenvironment. , 2019, European journal of cancer.
[71] N. Tinari,et al. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives , 2019, Journal of Hematology & Oncology.
[72] A. Tutt,et al. An innate-like Vδ1+ γδ T cell compartment in the human breast is associated with remission in triple-negative breast cancer , 2019, Science Translational Medicine.
[73] Zhi-gang Zhang,et al. The Diverse Function of PD-1/PD-L Pathway Beyond Cancer , 2019, Front. Immunol..
[74] Anping Li,et al. Prospects for combining immune checkpoint blockade with PARP inhibition , 2019, Journal of Hematology & Oncology.
[75] K. Weber,et al. A randomised phase II study investigating durvalumab in addition to an anthracycline taxane-based neoadjuvant therapy in early triple negative breast cancer - clinical results and biomarker analysis of GeparNuevo study. , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[76] E. Kohn,et al. A phase I study of the PD-L1 inhibitor, durvalumab, in combination with a PARP inhibitor, olaparib, and a VEGFR1–3 inhibitor, cediranib, in recurrent women’s cancers with biomarker analyses , 2019, Journal of Immunotherapy for Cancer.
[77] F. Bertucci,et al. PD-1/PD-L1 Targeting in Breast Cancer: The First Clinical Evidences are Emerging—A Literature Review , 2019, Cancers.
[78] H. Jacobs,et al. DNA damage tolerance in stem cells, ageing, mutagenesis, disease and cancer therapy , 2019, Nucleic acids research.
[79] A. Tan,et al. Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. , 2019, JAMA oncology.
[80] Y. Zou,et al. Disruption of Telomere Integrity and DNA Repair Machineries by KML001 Induces T Cell Senescence, Apoptosis, and Cellular Dysfunctions , 2019, Front. Immunol..
[81] H. Horlings,et al. Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial , 2019, Nature Medicine.
[82] B. Neel,et al. Phase I study of local radiation and tremelimumab in patients with inoperable locally recurrent or metastatic breast cancer , 2019, Oncotarget.
[83] E. Valtorta,et al. The Reproducibility of the Immunohistochemical PD-L1 Testing in Non-Small-Cell Lung Cancer: A Multicentric Italian Experience , 2019, BioMed research international.
[84] A. Shibata,et al. Novel Approaches to Improve the Efficacy of Immuno-Radiotherapy , 2019, Front. Oncol..
[85] A. Giobbie-Hurder,et al. Pembrolizumab plus trastuzumab in trastuzumab-resistant, advanced, HER2-positive breast cancer (PANACEA): a single-arm, multicentre, phase 1b-2 trial. , 2019, The Lancet. Oncology.
[86] E. Winer,et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[87] S. Loi,et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase II KEYNOTE-086 study , 2019, Annals of oncology : official journal of the European Society for Medical Oncology.
[88] J. Morales-Montor,et al. Immune Tumor Microenvironment in Breast Cancer and the Participation of Estrogen and Its Receptors in Cancer Physiopathology , 2019, Front. Immunol..
[89] Kuniaki Saito,et al. Alteration of specific cytokine expression patterns in patients with breast cancer , 2019, Scientific Reports.
[90] A. Bardia,et al. Sacituzumab Govitecan‐hziy in Refractory Metastatic Triple‐Negative Breast Cancer , 2019, The New England journal of medicine.
[91] A. Melcher,et al. ATR Inhibition Potentiates the Radiation-induced Inflammatory Tumor Microenvironment , 2019, Clinical Cancer Research.
[92] J. Lunceford,et al. T-Cell-Inflamed Gene-Expression Profile, Programmed Death Ligand 1 Expression, and Tumor Mutational Burden Predict Efficacy in Patients Treated With Pembrolizumab Across 20 Cancers: KEYNOTE-028. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[93] P. Hegde,et al. Development of a PD-L1 Complementary Diagnostic Immunohistochemistry Assay (SP142) for Atezolizumab , 2019, Applied immunohistochemistry & molecular morphology : AIMM.
[94] Eyyüb Y. Kibis,et al. Optimizing multi-modal cancer treatment under 3D spatio-temporal tumor growth. , 2019, Mathematical biosciences.
[95] M. Smyth,et al. Cancer immunoediting and resistance to T cell-based immunotherapy , 2018, Nature Reviews Clinical Oncology.
[96] S. Linn,et al. Neoadjuvant chemotherapy with or without anthracyclines in the presence of dual HER2 blockade for HER2-positive breast cancer (TRAIN-2): a multicentre, open-label, randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[97] E. V. Van Allen,et al. Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine , 2018, Genome Medicine.
[98] T. Yap,et al. Development of PARP and Immune-Checkpoint Inhibitor Combinations. , 2018, Cancer research.
[99] W. Han,et al. PD-L1 expression and the prognostic significance in gastric cancer: a retrospective comparison of three PD-L1 antibody clones (SP142, 28–8 and E1L3N) , 2018, Diagnostic Pathology.
[100] P. Ferrari,et al. Tumour growth and immune evasion as targets for a new strategy in advanced cancer. , 2018, Endocrine-related cancer.
[101] K. Tenbrock,et al. Reactive Oxygen Species as Regulators of MDSC-Mediated Immune Suppression , 2018, Front. Immunol..
[102] G. Mills,et al. State-of-the-art strategies for targeting the DNA damage response in cancer , 2018, Nature Reviews Clinical Oncology.
[103] Jing Liu,et al. Regulation of cancer immune escape: The roles of miRNAs in immune checkpoint proteins. , 2018, Cancer letters.
[104] M. Hung,et al. Exosomal PD-L1 harbors active defense function to suppress T cell killing of breast cancer cells and promote tumor growth , 2018, Cell Research.
[105] Wei Zhang,et al. Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response , 2018, Nature.
[106] P. V. van Diest,et al. Receptor Conversion in Distant Breast Cancer Metastases: A Systematic Review and Meta-analysis , 2018, Journal of the National Cancer Institute.
[107] A. Möller,et al. Breast Cancer-Derived Exosomes Alter Macrophage Polarization via gp130/STAT3 Signaling , 2018, Front. Immunol..
[108] K. Kabashima,et al. Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations , 2018, Front. Oncol..
[109] S. Loi,et al. Safety and Antitumor Activity of Pembrolizumab in Patients with Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Advanced Breast Cancer , 2018, Clinical Cancer Research.
[110] I. Holen,et al. The breast tumor microenvironment: role in cancer development, progression and response to therapy , 2018, Expert review of molecular diagnostics.
[111] L. Tang,et al. Decitibine improve the efficiency of anti-PD-1 therapy via activating the response to IFN/PD-L1 signal of lung cancer cells , 2018, Oncogene.
[112] S. Loi,et al. Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses , 2018, Front. Immunol..
[113] S. Swain,et al. Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE): a phase II, open-label, multicenter, multinational cardiac safety study , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.
[114] H. Peinado,et al. The influence of tumour-derived extracellular vesicles on local and distal metastatic dissemination. , 2017, Molecular aspects of medicine.
[115] S. Batra,et al. PD-L1, inflammation, non-coding RNAs, and neuroblastoma: Immuno-oncology perspective. , 2017, Seminars in cancer biology.
[116] T. Stokol,et al. Tissue Factor-Expressing Tumor-Derived Extracellular Vesicles Activate Quiescent Endothelial Cells via Protease-Activated Receptor-1 , 2017, Front. Oncol..
[117] P. Agostinis,et al. Cell death and immunity in cancer: From danger signals to mimicry of pathogen defense responses , 2017, Immunological reviews.
[118] L. Dirix,et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study , 2017, Breast Cancer Research and Treatment.
[119] J. Koo,et al. Clinicopathological and prognostic significance of programmed death ligand-1 expression in breast cancer: a meta-analysis , 2017, BMC Cancer.
[120] C. Bagni,et al. New insights into the metastatic behavior after breast cancer surgery, according to well-established clinicopathological variables and molecular subtypes , 2017, PloS one.
[121] Alain Viari,et al. Whole-Genome Sequencing Reveals Breast Cancers with Mismatch Repair Deficiency. , 2017, Cancer research.
[122] P. Ferrari,et al. Prognostic and predictive biomarkers in breast cancer: Past, present and future. , 2017, Seminars in cancer biology.
[123] R. Bell,et al. Oral, Head and Neck Oncology and Reconstructive Surgery , 2017 .
[124] L. Emens. Breast Cancer Immunotherapy: Facts and Hopes , 2017, Clinical Cancer Research.
[125] M. Shaul,et al. Neutrophils as active regulators of the immune system in the tumor microenvironment , 2017, Journal of leukocyte biology.
[126] Ludmila V. Danilova,et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade , 2017, Science.
[127] Jaime Rodriguez-Canales,et al. Comparison of Different Antibody Clones for Immunohistochemistry Detection of Programmed Cell Death Ligand 1 (PD-L1) on Non–Small Cell Lung Carcinoma , 2017, Applied immunohistochemistry & molecular morphology : AIMM.
[128] C. Denkert,et al. Molecular alterations in triple-negative breast cancer—the road to new treatment strategies , 2017, The Lancet.
[129] Sung-Bae Kim,et al. Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial. , 2017, The Lancet. Oncology.
[130] E. Kohn,et al. Safety and Clinical Activity of the Programmed Death-Ligand 1 Inhibitor Durvalumab in Combination With Poly (ADP-Ribose) Polymerase Inhibitor Olaparib or Vascular Endothelial Growth Factor Receptor 1-3 Inhibitor Cediranib in Women's Cancers: A Dose-Escalation, Phase I Study. , 2017, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[131] Thomas R. Cox,et al. Pre-metastatic niches: organ-specific homes for metastases , 2017, Nature Reviews Cancer.
[132] S. Fox,et al. Tumour-infiltrating lymphocytes and the emerging role of immunotherapy in breast cancer. , 2017, Pathology.
[133] P. Shah,et al. Prognostic role of neutrophil-to-lymphocyte ratio in breast cancer: a systematic review and meta-analysis , 2017, Breast Cancer Research.
[134] Richard Pazdur,et al. An FDA Perspective on the Regulatory Implications of Complex Signatures to Predict Response to Targeted Therapies , 2016, Clinical Cancer Research.
[135] C. Sotiriou,et al. Tumor-infiltrating lymphocyte composition, organization and PD-1/ PD-L1 expression are linked in breast cancer , 2016, Oncoimmunology.
[136] Xuetao Cao,et al. Characteristics and Significance of the Pre-metastatic Niche. , 2016, Cancer cell.
[137] Y. Shentu,et al. Prevalence of PD-L1 expression in patients with non-small cell lung cancer screened for enrollment in KEYNOTE-001, -010, and -024 , 2016 .
[138] A. Musolino,et al. Immunoglobulin G fragment C receptor polymorphisms and efficacy of preoperative chemotherapy plus trastuzumab and lapatinib in HER2-positive breast cancer , 2016, The Pharmacogenomics Journal.
[139] Y. Yarden,et al. The combination of trastuzumab and pertuzumab administered at approved doses may delay development of trastuzumab resistance by additively enhancing antibody-dependent cell-mediated cytotoxicity , 2016, mAbs.
[140] M. Iorio,et al. Exosome-mediated delivery of miR-9 induces cancer-associated fibroblast-like properties in human breast fibroblasts , 2016, Cell Death and Disease.
[141] Jonathan H. Esensten,et al. CD28 Costimulation: From Mechanism to Therapy. , 2016, Immunity.
[142] R. Weinberg,et al. Neutrophils Suppress Intraluminal NK Cell-Mediated Tumor Cell Clearance and Enhance Extravasation of Disseminated Carcinoma Cells. , 2016, Cancer discovery.
[143] S. Mocellin,et al. Activated T cells sustain myeloid-derived suppressor cell-mediated immune suppression , 2015, Oncotarget.
[144] A. Nicolini. Clinical and laboratory patterns during immune stimulation in hormone responsive metastatic breast cancer , 2015 .
[145] A. Tzankov,et al. Role of the Tumor Microenvironment in Breast Cancer , 2015, Pathobiology.
[146] B. Vogelstein,et al. PD-1 blockade in tumors with mismatch repair deficiency. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[147] C. Drake,et al. Immune checkpoint blockade: a common denominator approach to cancer therapy. , 2015, Cancer cell.
[148] O. Mandelboim,et al. Characterization of tumor infiltrating Natural Killer cell subset , 2015, Oncotarget.
[149] J. Bergh,et al. Breast cancer during follow-up and progression - A population based cohort on new cancers and changed biology. , 2014, European journal of cancer.
[150] Hui Li,et al. Noncanonical NF-κB Activation Mediates STAT3-Stimulated IDO Upregulation in Myeloid-Derived Suppressor Cells in Breast Cancer , 2014, The Journal of Immunology.
[151] P. Bragado,et al. Mechanisms of disseminated cancer cell dormancy: an awakening field , 2014, Nature Reviews Cancer.
[152] S. Sukumar,et al. Breast cancer cells condition lymphatic endothelial cells within pre-metastatic niches to promote metastasis , 2014, Nature Communications.
[153] F. Cardoso,et al. Time for more optimism in metastatic breast cancer? , 2014, Cancer treatment reviews.
[154] A. Schneeweiss,et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[155] Sung-Bae Kim,et al. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA study): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 study. , 2013, The Lancet. Oncology.
[156] M. Sznol,et al. Antagonist Antibodies to PD-1 and B7-H1 (PD-L1) in the Treatment of Advanced Human Cancer , 2013, Clinical Cancer Research.
[157] Yusuke Yoshioka,et al. Neutral Sphingomyelinase 2 (nSMase2)-dependent Exosomal Transfer of Angiogenic MicroRNAs Regulate Cancer Cell Metastasis , 2013, The Journal of Biological Chemistry.
[158] J. Blay,et al. Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. , 2012, Cancer research.
[159] J. Bergh,et al. When to order a biopsy to characterise a metastatic relapse in breast cancer. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.
[160] Chris Fellner. Ipilimumab (yervoy) prolongs survival in advanced melanoma: serious side effects and a hefty price tag may limit its use. , 2012, P & T : a peer-reviewed journal for formulary management.
[161] J. Bergh,et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[162] Mark Clemons,et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[163] J. Fournié,et al. Stimulated γδ T Cells Increase the In Vivo Efficacy of Trastuzumab in HER-2+ Breast Cancer , 2011, The Journal of Immunology.
[164] R. Wersto,et al. Tumor-evoked regulatory B cells promote breast cancer metastasis by converting resting CD4⁺ T cells to T-regulatory cells. , 2011, Cancer research.
[165] S. Ferrini,et al. Exocytosis of azurophil and arginase 1‐containing granules by activated polymorphonuclear neutrophils is required to inhibit T lymphocyte proliferation , 2011, Journal of leukocyte biology.
[166] R. Schreiber,et al. Cancer Immunoediting: Integrating Immunity’s Roles in Cancer Suppression and Promotion , 2011, Science.
[167] Aled Clayton,et al. Cancer exosomes trigger fibroblast to myofibroblast differentiation. , 2010, Cancer research.
[168] Karen Gelmon,et al. Metastatic behavior of breast cancer subtypes. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[169] P. Ferrari,et al. A new pharmacological approach to gastrointestinal cancer at high risk of relapse based on maintenance of the cytostatic effect , 2010, Tumor Biology.
[170] D. Ingber,et al. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[171] T. Tedder,et al. B Cells Are Required for Optimal CD4+ and CD8+ T Cell Tumor Immunity: Therapeutic B Cell Depletion Enhances B16 Melanoma Growth in Mice , 2010, The Journal of Immunology.
[172] Y. Matsuki,et al. Secretory Mechanisms and Intercellular Transfer of MicroRNAs in Living Cells*♦ , 2010, The Journal of Biological Chemistry.
[173] K. Gelmon,et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[174] G. Cheng,et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN. , 2009, Cancer cell.
[175] G. Zhu,et al. B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells. , 2008, Blood.
[176] Chin-Yo Lin,et al. Gene expression preferentially regulated by tamoxifen in breast cancer cells and correlations with clinical outcome. , 2006, Cancer research.
[177] C. Perou,et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. , 2006, JAMA.
[178] S. Rafii,et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche , 2005, Nature.
[179] A. Nicolini,et al. Beta-interferon and interleukin-2 prolong more than three times the survival of 26 consecutive endocrine dependent breast cancer patients with distant metastases: an exploratory trial. , 2005, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.
[180] A. Nicolini,et al. An Immunotherapy Schedule in Endocrine-Dependent Metastatic Breast Cancer: Correlation Between Clinical Course and Immunologic Parameters , 2005, Journal of immunotherapy.
[181] George Coukos,et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival , 2004, Nature Medicine.
[182] R. Schreiber,et al. Cancer immunoediting: from immunosurveillance to tumor escape , 2002, Nature Immunology.
[183] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[184] L. Presta,et al. Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets , 2000, Nature Medicine.
[185] J. Baselga,et al. Trastuzumab, a humanized anti-HER2 monoclonal antibody, for the treatment of breast cancer. , 1999, Drugs of today.
[186] R. Finn,et al. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs , 1998, Oncogene.
[187] C. Arteaga,et al. p185c-erbB-2 signal enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair. , 1994, Cancer research.
[188] R Akita,et al. Her-2/neu expression in node-negative breast cancer: direct tissue quantitation by computerized image analysis and association of overexpression with increased risk of recurrent disease. , 1993, Cancer research.
[189] S. Rosenberg,et al. Expansion of human tumor infiltrating lymphocytes for use in immunotherapy trials. , 1987, Journal of immunological methods.
[190] D. Dunlop. RECENT ADVANCES IN TREATMENT , 1955 .
[191] P. Ferrari,et al. Final results of a 2:1 control-case observational study using interferon beta and interleukin-2, in addition to first-line hormone therapy, in estrogen receptor-positive, endocrine-responsive metastatic breast cancer patients , 2022, Journal of Cancer Metastasis and Treatment.
[192] E. Timperi,et al. The Immune Landscape in Women Cancers. , 2020, Cancer treatment and research.
[193] E. Elgabry,et al. Long-term Clinical Outcomes and Biomarker Analyses of Atezolizumab Therapy for Patients With Metastatic Triple-Negative Breast Cancer: A Phase 1 Study , 2019, JAMA oncology.
[194] M. Beckmann,et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. , 2018, The Lancet. Oncology.
[195] Anne Floquet,et al. Rucaparib in relapsed, platinum-sensitive high-grade ovarian carcinoma (ARIEL2 Part 1): an international, multicentre, open-label, phase 2 trial. , 2017, The Lancet. Oncology.
[196] E. Tartour,et al. Immunomodulatory Activity of VEGF in Cancer. , 2017, International review of cell and molecular biology.
[197] X. Zhang,et al. Repurposing Antiestrogens for Tumor Immunotherapy. , 2017, Cancer discovery.
[198] Saz Parkinson Zuleika Esther,et al. European Guidelines for Breast Cancer Screening and Diagnosis - the European Breast Guidelines , 2016 .
[199] L. Downs,et al. A phase II study of allogeneic natural killer cell therapy to treat patients with recurrent ovarian and breast cancer. , 2011, Cytotherapy.
[200] G. Freeman,et al. The B7 family revisited. , 2005, Annual review of immunology.
[201] J. Goldie,et al. Quantitative model for multiple levels of drug resistance in clinical tumors. , 1983, Cancer treatment reports.
[202] J H Goldie,et al. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate. , 1979, Cancer treatment reports.